Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac083 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Tatsuya Atsumi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Inc., Foster City, CA.
Abstract (Originalsprache)
Objectives
To evaluate the long-term safety and efficacy of filgotinib (FIL) for Japanese patients with rheumatoid arthritis (RA) and limited/no prior methotrexate (MTX) exposure. We present a Japanese population subanalysis of a global randomised-controlled trial at Week 52 and interim long-term extension (LTE) to Week 48 through June 2020.
Methods
Patients were randomised to FIL 200 mg plus MTX, FIL 100 mg plus MTX, FIL 200 mg, or MTX for 52 weeks. At completion, eligible patients could enrol in the LTE. Those receiving FIL continued; those receiving MTX were rerandomised (blinded) to FIL 200 or 100 mg upon discontinuation of MTX. After a 4-week washout period, MTX could be re-added.
Results
Adverse event rates at Week 52 and in the LTE to Week 48 were comparable across treatment groups. Week 52 American College of Rheumatology 20% improvement (ACR20) rates were 83% (19/23), 82% (9/11), 75% (9/12), and 76% (19/25) for FIL 200 mg plus MTX, FIL 100 mg plus MTX, FIL 200 mg, and MTX, respectively. Through LTE Week 48, ACR20 rates were maintained.
Conclusions
In the 56 Japanese patients treated with FIL, efficacy was maintained through Week 52 and beyond, with no increases in the incidence of adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.
- First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
- Department of Orthopedics, Matsubara Mayflower Hospital, Hyogo, Japan.
- Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Aichi Developmental Disability Center, Kasugai, Aichi, Japan.
- Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
ORCID-Profile: Yoshiya Tanaka, Kunihiro Yamaoka
Förderung
- Gilead Sciences, Inc., Foster City, CA
Zitieren
APA
Atsumi, T., Tanaka, Y., Matsubara, T., Amano, K., Ishiguro, N., Sugiyama, E., Yamaoka, K., Westhovens, R., Ching, D. W. T., Messina, O. D., Burmester, G. R., Genovese, M., Bartok, B., Pechonkina, A., Kondo, A., Yin, Z., Gong, Q., Tasset, C., & Takeuchi, T. (2023). Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3). Modern Rheumatology. https://doi.org/10.1093/mr/roac083
Vancouver
Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, et al. Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3). Modern Rheumatology. 2023. doi:10.1093/mr/roac083
BibTeX
@article{Atsumi2023,
author = {Atsumi, Tatsuya and Tanaka, Yoshiya and Matsubara, Tsukasa and Amano, Koichi and Ishiguro, Naoki and Sugiyama, Eiji and Yamaoka, Kunihiro and Westhovens, René and Ching, Daniel W T and Messina, Osvaldo Daniel and Burmester, Gerd R and Genovese, Mark and Bartok, Beatrix and Pechonkina, Alena and Kondo, Akira and Yin, Zhaoyu and Gong, Qi and Tasset, Chantal and Takeuchi, Tsutomu},
title = {Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac083}
}
EUVIMED